Intronic PRRT2 mutation generates novel splice acceptor site and causes paroxysmal kinesigenic dyskinesia with infantile convulsions (PKD/IC) in a three generation family by Weber, Axel et al.
CASE REPORT Open Access
Intronic PRRT2 mutation generates novel
splice acceptor site and causes paroxysmal
kinesigenic dyskinesia with infantile
convulsions (PKD/IC) in a three generation
family
Axel Weber1*, Jonas Kreth2 and Ulrich Müller1
Abstract
Background: Mutations in PRRT2 cause autosomal dominant paroxysmal kinesigenic dyskinesia with infantile
convulsions (PKD/IC).
Case presentation: A previously not recognized intronic PRRT2 mutation (c.880-35G > A; p.S294Lfs*29) was found
in an 18 month old girl with IC and in her mother with classical presentation of PKD. The mutation results in a
novel splice acceptor site in intron 2 of PRRT2. Due to frameshift and a subsequent premature stop-codon the
resulting transcript appears to render the PRRT2 protein non/dysfunctional and is the likely cause of disease in this
family.
Conclusion: Our findings expand the mutational spectrum of this disease.
Keywords: Paroxysmal kinesigenic dyskinesia (PKD), Infantile convulsions (IC), PKD/IC, Dystonia 10, PRRT2, Novel
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Background
Benign infantile afebrile convulsions and kinesigenic
dystonia are the hallmarks of paroxysmal kinesigenic
dyskinesia with infantile convulsions (PKD/IC, dystonia
10; OMIM #128200, #605751 and #602066). Onset of
convulsions (IC) is commonly during the first year of
life. Kinesigenic involuntary movements (PKD) develop
somewhat later in early childhood. While convulsions
usually resolve by 2 years of age, abnormal movements
occur throughout life. PKD manifests as brief (less than
a minute) but frequent (up to 100/day) dystonic and
choreatiform attacks that are precipitated by abrupt
movements.
PKD/IC is inherited as an autosomal dominant trait
with high penetrance. The disease locus was assigned to
the short arm of chromosome 16 and a positional cloning
approach has identified PRRT2 as the underlying disease
gene [1–3] PRRT2 encodes “proline-rich transmembrane
protein 2” and appears to be required for normal synapse
function.
PRRT2 mutations identified in PKD/IC to date include
frameshift, missense and splice site mutations and most
commonly a C insertion (c.649-650insC) (reviewed in [4]).
Furthermore microdeletions at chromosome 16p11.2 are
known to cause PKD/IC [5, 6]. Known splice site muta-
tions affect the well established splice donor (GT) and
splice acceptor (AG) sites. Here we describe an intronic
PRRT2 mutation in PKD/IC that generates a novel splice
acceptor site which alters the transcript.
Case presentation
The proposita was born after 37 weeks of an uneventful
pregnancy to non-consanguineous parents. She weighed
2500 g (15th percentile), her length was 45 cm (3rd to
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15th percentile) and her head circumference 33 cm (25th
to 50th percentile). First afebrile convulsions occurred at
age 6 months. They lasted up to 3 min and resolved spon-
taneously. Convulsions were mainly generalized, did not
start focally, and were followed by muscular atonia and
cyanosis. Muscle tone was normal between attacks.
Cerebrospinal fluid analysis, auditory screening, EEG and
cranial MRI were normal. Inborn errors of metabolism
were excluded. She does not display developmental delay.
No convulsions occurred during medication with oxcarba-
cepine (daily dose: 10 mg per kilogram of body weight).
The proposita’s mother is affected by early-onset gen-
eralized paroxysmal dystonia. She was born in 1977, de-
veloped normally during childhood and did not have
afebrile benign or febrile convulsions. At nine years of
age she developed dystonic episodes triggered by sudden
passive movements, stress, and fright. The involuntary
movements lasted for up to 20 s. There was no infringe-
ment of consciousness during episodes. The attacks oc-
curred daily. Muscle tone was normal between attacks.
Medication with oxcarbacepine (daily dose: 300 mg)
abolished attacks entirely.
Although the maternal grandfather could not be exam-
ined, he is reported to have suffered from episodic dyski-
nesias as well, similar to the mother’s episodes in terms
of age of onset, appearance and duration. Based on the
mother’s statement no additional family members are
known to have neurological symptoms.
Materials and methods
DNA was isolated from EDTA blood by standard
methods (QIAGEN DNA-Blood and Tissue Kit). RNA
was isolated from PAX-Blood using the RNeasy mini Kit
of QIAGEN. Reverse transcription was performed fol-
lowing a standard protocol using SuperScript-III reverse
transcriptase (Thermofisher) and random hexamer
primers (Thermofisher). Dideoxy sequencing was per-
formed according to standard procedures. Primers for
amplification and sequencing of the genomic sequence
of PRRT2 exons and adjacent intronic sequences were




Multiple alignment of 100 vertebrate species and mea-
surements of evolutionary conservation of guanine at
position was performed applying the UCSC Vertebrate
Multiz Alignment & Conservation tool at (http://geno-
me.ucsc.edu/index.html). The multiple alignments were
generated using multiz and other tools available through
the UCSC/Penn State Bioinformatics comparative gen-
omics alignment pipeline.
Results and discussion
DNA sequencing in the proposita and her mother revealed
a G-A transition in intron 2 of PRRT2 (Fig. 1). This base
change is located 35 base pairs upstream of the wild-type
splice acceptor site (AG) of exon 3 [hg19: chr16:2
9825620G >A (PRRT2 c.880-35G >A; p.S294Lfs*29)] (Fig. 1).
G at this position is evolutionarily highly conserved and
identical in almost all vertebrates tested. No variant found
generated a novel consensus AG-splice acceptor site.
Furthermore, the G-A change is not listed in public data-
bases (NCBI, DGV, dbSNP). Substitution of G by A at this
Fig. 1 a Electropherogram of intron 2/exon3 sequence of PRRT2 in the patient. Note the G > A transition (arrow) c.880-35G > A. b Different sized
wild-type (=179 bp) and mutant (=211 bp) PCR products on an ethidium bromide stained gel. Lane 1: molecular weight standard (MW), Lane 2:
positive control DNA (human placental), Lane 3: negative control (water), Lane 4–6: DNA of the family members investigated. c Novel splice acceptor
site due to c.880-35G > A and altered sequence of exon 3 of the PRRT2 transcript
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position is predicted to result in the generation of a novel
consensus splice acceptor site (AG). The Alternative Splice
Site Predictor (ASSP) [7] assigned a score of 8.170 (confi-
dence 0.456) to the new splice acceptor site. This was even
higher than the score of 4.192 (confidence 0.330) calculated
for the wild-type site.
In order to test the prediction of a functional new
splice acceptor site we performed RT-PCR analysis using
RNA extracted from the patient’s and her mother’s lym-
phocytes. As shown in figure, mRNAs of two sizes were
found. One corresponds to the wild-type transcript, the
second one is extended by 36 bases thus confirming that
it was generated by splicing of exon 2 to the novel splice
acceptor site in intron 2. Fig. also shows the one band
found in unaffected persons, such as in a control and in
the patient’s unaffected father (Fig. 1). Splicing to this
novel site results in a frameshift and premature termin-
ation of the amino acid chain.
Although the proposita and her mother carried the
identical mutation, the patients’ phenotype differed.
While the proposita displayed the classical picture of IC,
followed by PKD, the mother and her father had PKD
only. Different phenotypes in the presence of identical
mutations of “disease genes” are a common finding in
most monogenic disorders probably owing to modifier
genes and environmental factors. In the case of PRRT2
mutations an entire spectrum of diseases has been de-
scribed in addition to PKD/IC. These diseases include
familial hemiplegic migraine, benign paroxysmal torti-
collis, episodic ataxia and paroxysmal non-kinesigenic
dyskinesias [8]. Unlike the observations in the present
family, it might be that at least some of these highly vari-
able phenotypes are also associated with mutations in
specific regions of PRRT2 in addition to modifier genes
and environmental factors.
Conclusion
In conclusion we have described a novel mutation in
PRRT2 that results in a larger transcript of the gene.
Abnormal function of the predicted altered PRRT2 pro-
tein appears to cause PKD/IC probably by a dominant
negative effect.
Consent
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their written consent to have their clinical histories
published.
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